首页> 中文期刊> 《中国医药导报》 >输血后丙型肝炎60例临床分析

输血后丙型肝炎60例临床分析

         

摘要

Objective: To discuss the disease development and the clinical effect of the pos t-transfusion hepatitis C.Methods: 60 cases of post-transfusion hepatitis C were selected, and their disease development and the clinical effect were analyzed. Results: All the 60 cases were diagnosed post-transfusion chronic hepatitis C, when they came to our hospital,18 cases of them were diagnosed liver cirrhosis, 12 cases of them were diagnosed primary liver cancer. The improvement rate of the patients with liver cirrhosis was 11.11%, the improvement rate of the patients without liver cirrhosis was 54.76%, showed significant difference (X2=5.37, P<0.05). The improvement rate of the 60 cases was 41.67%. Conclusion:The blood should be strictly checked before it will be inputed into the patients, and indications should be abided strictly,conventional liver protecting treatment should be done to the patients with HCV.%目的:探讨输血后丙型肝炎患者疾病转归及治疗效果.方法:选择本院2001年1月~2009年12月收治的输血后丙型肝炎患者60例,分析其病情进展及临床治疗效果.结果:所有患者均诊断为输血后慢性丙型肝炎,至入院时已发展为肝硬化18例,发展为肝癌12例;入院时即有肝硬化者18例,治疗好转率为11.11%,入院时未出现肝硬化者42例,治疗好转率为54.76%,未合并肝硬化者治疗有效率高于已合并肝硬化者,差异具有统计学意义(χ2=5.37,P<0.05).60例患者治疗有效率为41.67%.结论:血液采集前需严格检查,严格掌握输血适应证,预防输血导致丙型肝炎病毒的感染,患者感染丙型肝炎病毒后,需常规进行保肝、抗纤维化治疗,以延缓病情进展,提高患者生存质量.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号